HPV-16早期基因E1在果蝇细胞S2中的表达和鉴定

目的:在果蝇S2细胞中表达人乳头瘤病毒16型(HPV-16)E1。方法:PCR扩增HPV-16 E1全长,将PCR产物连接至pMD18-T并测序鉴定,继而将HPV-16 E1构建至果蝇表达载体pMT/Bip/V5-HisA中。大量提取pMT/Bip/V5/His-E1重组表达载体并与筛选质粒pCoBlast共转染果蝇S2细胞,经杀稻瘟菌素(Blasticidin S)筛选获得具有抗性的稳定转染S2细胞。提取稳转S2细胞基因组DNA,PCR鉴定S2细胞中整合的E1。以终浓度为5μmol/L CdCl2诱导表达,收集上清进行SDS-PAGE及Western blot鉴定。结果:双酶切及测序结果显示HPV-16 E1基因已克隆人重组质粒pMT/Bip/V5-E1,PCR和Western blot结果表明HPV-16 E1基因已整合至果蝇S2细胞基因组并稳定表达。结论:获得HPV-16 E1转染的果蝇S2细胞株,该细胞株可持续稳定表达E1蛋白。     

牛病毒性腹泻病毒E^rns-E2融合蛋白在果蝇S2细胞中的表达与鉴定

目的：利用果蝇S2细胞表达牛病毒性腹泻病毒（BVDV）Erns-E2融合蛋白,并对其抗体结合能力进行鉴定。方法：用RT-PCR方法扩增BVDV NADL株Erns和E2蛋白的编码基因,利用（G4-S）3柔性15肽基因将扩增的2个基因连接,再与昆虫表达载体pMT/BiP/V5-His连接构建重组表达载体pMT/BiP/V5-His-Erns-E2,将后者与筛选质粒pCoBlast共转染果蝇S2细胞后表达Erns-E2融合蛋白,并对表达产物进行鉴定。结果：SDS-PAGE结果表明,融合蛋白相对分子质量为76800;Western blotting检测表明,该融合蛋白具有与BVDV抗体良好的结合能力。结论：BVDV的Erns-E2融合蛋白能在果蝇S2细胞中进行表达;经鉴定,表达产物具有良好的抗体结合能力,可用于抗原检测。     

牛病毒性腹泻病毒Erns-E2融合蛋白在果蝇S2细胞中的表达与鉴定

目的:利用果蝇S2细胞表达牛病毒性腹泻病毒(BVDV)Erns-E2融合蛋白,并对其抗体结合能力进行鉴定.方法:用RT-PCR方法扩增BVDV NADL株Erns和E2蛋白的编码基因,利用(G4-S)3柔性15肽基因将扩增的2个基因连接,再与昆虫表达载体pMT/BiP/V5-His连接构建重组表达载体pMT/BiP/V5-His-E(MS)-E2,将后者与筛选质粒pCoBlast共转染果蝇S2细胞后表达Erns-E2融合蛋白.并对表达产物进行鉴定.结果:SDS-PAGE结果表明,融合蛋白相对分子质量为76 800;Westem blotting检测表明,该融合蛋白具有与BVDV抗体良好的结合能力.结论:BVDV的Erns-E2融合蛋白能在果蝇S2细胞中进行表达;经鉴定,表达产物具有良好的抗体结合能力,可用于抗原检测.     

表达中国流行株HIV-1 gp120外膜蛋白靶细胞模型的建立

利用pDispaly真核表达载体构建了用于表达中国流行株HIV-1 gp120的真核表达质粒pD-120,通过脂质体转染法将其导入人宫颈癌细胞（HeLa）,经G418反复加压筛选,直到细胞不再死亡为止,8代后获得稳定表达中国流行株HIV-1gp120蛋白的靶细胞复制模型HeLa-gp,SDS-PAGE、蛋白印迹与间接免疫荧光分析表明,重组蛋白得到很好表达,并具有良好生物活性。本研究为抗AIDS/HIV治疗用基因工程制剂或靶向药物的活性检测奠定了坚实基础。     

家蚕微孢子虫极管蛋白1 (NbPTP1) 在果蝇S2细胞中的表达与糖基化修饰

极管蛋白(Polar tube protein)是极管的主要成分,能特异性定位于微孢子虫极管,在微孢子虫侵染宿主过程中发挥重要作用。文中分析了家蚕微孢子虫极管蛋白1中潜在的O-、N-糖基化修饰位点,克隆了家蚕微孢子虫极管蛋白1全基因序列,并将其插入带有V5和His标签的真核表达载体pMT/Bip/V5-His A中,成功构建了pMT/Bip/V5-His A-NbPTP1重组质粒,经转染果蝇S2细胞后,发现NbPTP1基因能在果蝇细胞中高效表达。此外,Lectin blotting和β-消除反应分析结果表明:果蝇S2细胞内表达的NbPTP1具有O-糖基化修饰特征。以上结果为研究NbPTP1的糖基化修饰特征与其功能之间的关系提供了基础,有助于揭示微孢子虫侵染机制,建立可行有效的微孢子虫病诊断和防治措施。     

可溶性尿激酶受体的表达、纯化和结晶

克隆尿激酶受体可溶区域(suPAR)到果蝇胚胎细胞分泌表达载体pMT/Bip/v5-his,重组质粒与pCoHygro共转染果蝇S2细胞,筛选多拷贝稳定表达细胞系suPARS2.suPAR表达蛋白经尿激酶N端片段亲和柱、ResourceQ阴离子交换柱两步纯化后,得到高纯度的、稳定的suPAR单体.纯化后的蛋白质,与其抗体ATN615及尿激酶N端片段结构域等摩尔混合,浓缩至10g/L,以透析法进行该三元复合物晶体生长,获得衍射分辨率为1.9#的蛋白质晶体.     

重组HIV表面抗原gp120的表达纯化及免疫学鉴定

为研制具有流行特点的HIV血清学诊断试剂,采用pET系统表达HIV-1表面糖蛋白gp120。研究发现,全长的gp120在E.coli中不能有效表达;N端半长的gp120可以表达,但表达量很低;仅保留N端1/3的gp120(包含gp120V1/V2抗原决定簇)有效表达,表达蛋白占菌体总蛋白的18%;Westernblot显示较好的反应原性;通过金属螯合层析,产物得到完全纯化。在这些结果的基础上,我们表达了流行株的gp120片段,为探索gp120在大肠杆菌的高效表达,建立针对中国人群的HIV血清学诊断系统奠定基础。     

重组人PCNA突变体的克隆与稳定表达

目的:构建重组人PCNA突变体(mutant PCNA,mPCNA)的真核表达质粒,并建立稳定高表达该目的蛋白的宫颈癌细胞系Hela.为进一步研究PCNA在DNA损伤修复中重要的生物学功能奠定基础.方法:将舍有定点突变的PCNA cDNA序列克隆到T载体中,然后再亚克隆到真核表达栽体pCDNA3.1/V5-His A上,构建真核表达载体质粒pCDNA3.1/V5-His A-mPCNA,稳定转染到Hela细胞中;Western Blotting法检测蛋白的表达情况;白细胞记数法测定细胞的生长速率.结果:真核表达质粒pCDNA3.1/V5-His A-mPCNA经酶切、测序分析与实验设计的序列完全一致;稳定建系后,Western Blotting结果显示在相应位置可见清楚的目的条带;稳定高表达mPCNA的细胞系与野生型细胞相比两者的生长速率基本一致.结论:成功构建了真核表达质粒pCDNA3.1/V5-His A-mPCNA;建立了稳定高表达该突变体的Hela细胞系;PCNA突变体的高表达不影响Hela细胞的正常生长.     

Ag85A真核表达重组体的构建及稳定转染细胞系的建立

构建结核杆菌抗原85A（AgS5A）的真核表达重组体,转染L929细胞,建立稳定转染细胞系。从质粒V1 Jns．tPA—Ag85A中经PCR扩增出Ag85A基因,利用DNA重组技术将其插入到真核表达载体peDNA3．1／myc—HisA中,经酶切和测序鉴定后,脂质体转染法转染L929细胞,通过G418选择培养,建立稳定转染细胞系,Western Blot检测Ag85A的表达。成功构建pcDNA3．1／mye—HisA—Ag85A真核表达载体并稳定转染L929细胞,成功表达了目的基因。为进一步研究Ag85ADNA疫苗对结核杆菌的免疫防护作用奠定了基础。     

重组HIV表面抗原gp120的表达纯化及免疫学鉴定

为研制具有流行特点的HIV血清学诊断试剂,采用pET系统表达HIV－1表达糖蛋白gp120。研究发现,全长的gp120在E.coli中不能有效表达;N端半长的gp120可以表达,但表达量很低;仅保留N端1／3的gp120（包含gp120V1／V2抗决定簇）有效表达,表达蛋白占菌体总蛋白的18％;Western blot显示较好的反应原性;通过金属螯合层析,产物得到完全纯化。在这些结果的基础上,我们表达了流行株的gp120片段,为探索gp120在大肠杆菌的高效表达,建立针对中国人群的HIV血清学诊断系统奠定基础。     

HIV-1-gp120在重组杆状病毒系统中的表达

将中国株HIV 1B亚型 gp1 2 0全基因序列克隆到杆状病毒转座载体pFastBacI中多角体启动子下游 ,构建成重组转座载体 pFastBacI gp1 2 0 ,利用细菌 /杆状病毒 (BactoBac)表达系统筛选重组杆状病毒 ,在昆虫细胞Sf9中高效表达了HIV 1的外膜糖蛋白 gp1 2 0 ,SDS -PAGE和Westernblot分析结果一致 ,证明表达了 2种糖基化程度不同的 gp1 2 0。     

Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops

The gp120 envelope glycoprotein of primary human immunodeficiency virus type 1 (HIV-1) promotes virus entry by sequentially binding CD4 and the CCR5 chemokine receptor on the target cell. Previously, we adapted a primary HIV-1 isolate, ADA, to replicate in CD4-negative canine cells expressing human CCR5. The gp120 changes responsible for CD4-independent replication were limited to the V2 loop-V1/V2 stem. Here we show that elimination of a single glycosylation site at asparagine 197 in the V1/V2 stem is sufficient for CD4-independent gp120 binding to CCR5 and for HIV-1 entry into CD4-negative cells expressing CCR5. Deletion of the V1/V2 loops also allowed CD4-independent viral entry and gp120 binding to CCR5. The binding of the wild-type ADA gp120 to CCR5 was less dependent upon CD4 at 4 degrees C than at 37 degrees C. In the absence of the V1/V2 loops, neither removal of the N-linked carbohydrate at asparagine 197 nor lowering of the temperature increased the CD4-independent phenotypes. A CCR5-binding conformation of gp120, achieved by CD4 interaction or by modification of temperature, glycosylation, or variable loops, was preferentially recognized by the monoclonal antibody 48d. These results suggest that the CCR5-binding region of gp120 is occluded by the V1/V2 variable loops, the position of which can be modulated by temperature, CD4 binding, or an N-linked glycan in the V1/V2 stem.     

中国株HIV-1外膜蛋白真核表达载体的构建与表达

To construct the eukaryotic expression vector of HIV-1 gp120 gene and observe its expression in vitro, the recombinant expression vector pVAX1GP120 was constructed by inserting the gp120 gene into the eukaryotic expression vector pVAX1. The pVAX1GP120 was transfected into Vero cells by lipofectamine and the expressed product was detected by indirect immunofluore- scence.Restriction enzymes digestion analysis and sequencing results revealed that the recombinant expression vector pVAX1GP120 has been constructed successfully. The indirect immunofluorescence result showed green fluorescence on the membrane of transfected cells. The constructed eukaryotic expression vector of HIV-1 gp120 can be expressed in vitro, which lay the foundation for the further study of HIV-1 DNA vaccine.     

人单链白细胞介素12基因在果蝇细胞中的表达

用PCR方法扩增不含信号肽序列的hscIL-12基因,并装载到果蝇表达质粒pMT/Bip/V5中,将其转化黑腹果蝇细胞S2中进行分泌表达,以淋巴细胞增殖实验检测表达的hscIL-12的生物学活性,结果表明hscIL-12可促进淋巴细胞增殖,呈剂量依赖性（P＜0.05 ),提示在果蝇系统中表达的hscIL-12具有与天然IL－12相同的生物学活性,有良好的研究和临床应用前景。     

登革病毒衣壳蛋白靶向核酸酶表达系统的建立及应用

根据登革 2型病毒衣壳蛋白C基因和葡萄球菌核酸酶SN基因序列设计引物 ,从构建的原核表达载体pLEX D2C SN中扩增获得编码登革病毒衣壳蛋白和葡萄球菌核酸酶的融合基因D2C SN ,将其插入到真核表达载体pcDNA6 V5 His中 ,筛选获得重组质粒pcDNA D2C SN .电穿孔转染BHK细胞后 ,5mg Lblasticidin压力筛选 ,通过RT PCR、间接免疫荧光和免疫印迹鉴定表达的蛋白 ,体外DNA消化试验检测核酸酶活性 .结果表明 ,融合蛋白D2C SN在BHK细胞中获得了稳定表达 ,表达的融合蛋白能够被抗登革病毒衣壳蛋白的单克隆抗体特异识别 ,并具有良好的核酸酶活性 ,能够对DNA进行切割 .同时 ,BHK细胞中稳定表达的融合蛋白D2C SN能够有效抑制登革病毒的增殖 ,使其感染性降低 10 3 ～ 10 4倍 .这些结果为进一步将衣壳蛋白靶向病毒灭活策略应用于人类抗登革病毒感染奠定了基础     

Identification of the potential regions of Epap-1 that interacts with V3 loop of HIV-1 gp120

Early pregnancy associated protein-1 (Epap-1), a 90 kDa glycoprotein present in first trimester placental tissue, inhibits HIV-1 entry through interaction with HIV-1 gp120 at V3 and C5 regions. In the present study, we have identified the specific 32 mer region of Epap-1 that can interact with V3 loop. This was achieved by docking between Epap-1 molecular model and gp120 and studying the interaction of peptides with gp120 in vitro. Out of four peptides analyzed, two peptides (P-2 and P-3) showed significant interaction with V3 domain (N = 8; N = 7) of gp120. In the studies conducted using soluble gp120 and virus, peptide P-2 has shown conserved interaction at V3 loop regions recognized by 257D and F425 antibodies and higher anti-viral activity. Also, P-2 inhibited cell fusion mediated dye transfer between gp120 expressing HL2/3 and CD4 expressing Sup T1 cells suggesting its inhibition of viral entry, which is further confirmed by its action on HIV infection mediated by Tat activated beta gal expression in TZM-bl cells. Further optimization of P-2 peptide showed that the anti-viral activity and gp120 interaction residues lie in the N-terminal region of the peptide. These results together suggest that P-2 inhibits viral entry through specific interaction at V3 loop region.     

Human immunodeficiency virus strains differ in their ability to infect CD4+ cells expressing the rat homolog of CXCR-4 (fusin).

A clade B strain of human immunodeficiency virus type 1 (HIV-1(LAI)) could infect CD4+ cells expressing human CXCR-4 (fusin) or its rat homolog with similar efficacy. By contrast, cells expressing rat CXCR-4 were not permissive to HIV-1(NDK) (clade D), HIV-2(ROD), or HIV-1(LAI) with chimeric envelope protein gp120 bearing the V3 domain from HIV-1(NDK). The reciprocal chimeric gp120 (HIV-1(NDK) with V3 from HIV-1(LAI)) could mediate infection of cells expressing either human or rat CXCR-4. Genetically divergent HIV strains have different requirements for interaction with the CXCR-4 coreceptor, and the gp120 V3 domain seems to be involved in this interaction.     

Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.

The CD4 molecule is an essential receptor for human immunodeficiency virus type 1 (HIV-1) through high-affinity interactions with the viral external envelope glycoprotein gp120. Previously, neutralizing monoclonal antibodies (MAbs) specific to the third hypervariable domain of gp120 (the V3 loop) have been thought to block HIV infection without affecting the binding of HIV particles to CD4-expressing human cells. However, here we demonstrate that this conclusion was not correct and was due to the use of soluble gp120 instead of HIV particles. Indeed, neutralizing anti-V3 loop MAbs inhibited completely the binding and entry of HIV particles into CD4+ human cells. In contrast, the binding of virus was only partially inhibited by neutralizing anti-CD4 MAbs against the gp120 binding site in CD4, which, like the anti-V3 loop MAbs, completely inhibited HIV entry and infection. Nonneutralizing control MAbs against either the V3 loop or the N or C terminus of gp120 had no significant effect on HIV binding and entry. HIV-1 particles were also found to bind human and murine cells expressing or not expressing the human CD4 molecule. Interestingly, the binding of HIV to CD4+ murine cells was inhibited by both anti-V3 and anti-CD4 MAbs, whereas the binding to human and murine CD4- cells was affected only by anti-V3 loop MAbs. The effect of anti-V3 loop neutralizing MAbs on the HIV binding to cells appears not to be the direct consequence of gp120 shedding from HIV particles or of a decreased affinity of CD4 or gp120 for binding to its surface counterpart. Taken together, our results suggest the existence of CD4-dependent and -independent binding events involved in the attachment of HIV particles to cells; in both of these events, the V3 loop plays a critical role. As murine cells lack the specific cofactor CXCR4 for HIV-1 entry, other cell surface molecules besides CD4 might be implicated in stable binding of HIV particles to cells.